




STUDY ON THE EFFECTIVENSS OF NEBULIZED FENTANYL CITRATE AS 








DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE 




SCHOOL OF MEDICAL SCIENCES 









Alhamdulilah, utmost gracious to Rabb, ALLAH Almighty for His showers of blessings 
and graces. Alhamdulillah. 
I would like to express sincerest gratitude to my supervisor, Dr Abu Yazid Md Noh for all the 
help, support and guidance. Indeed I am lucky to have such easy going mentor who gave me 
all the freedom and spaces in conducting this research. All your effort in making this study 
successful is appreciated. 
To my family especially my mother, Puan Maimunah Saidin, thank you for the never ending 
support and encouragement since then till now in all the hardships and obstacles that I have 
been through. 
Last but not least, my son, Raden Muhammad Syaqil Rizqin. Through you, I am a better 
person today. 












TABLE OF CONTENTS 
TITLE           i 
ACKNOWLEDGEMENT        ii 
TABLE OF CONTENTS        iii 
Abstrak (Bahasa Melayu)         v 
Abstract (English)          vi 
Chapter 1: INTRODUCTION        1 
1.1: Introduction         1 
1.2  literature review        2 
1.3  Justification of study        6 
1.4  Objectives of study       8 
Chapter 2: STUDY PROTOCOL        9 
2.1   Study protocol submitted for ethical approval   9  
2.2  Ethical approval letter       42 
Chapter 3: MANUSCRIPT        45 
 3.1 Title page         45 
3.2  Abstract         47 
3.3  Introduction         48 
3.4  Methodology         49 





3.6  Discussion         61 
3.7  Conclusion         66 
3.8  Reference         67 
3.9 Abbreviations        71 
Chapter 4: APPENDICES         72 
4.1   Selected journal format (Singapore Medical Journal)   73 
4.2  Parent information and consent form     83 
4.3       Assent form        98 



















Pengenalan: Kajian ini adalah bertujuan untuk meneliti keberkesanan sedutan fentanyl citrate 
di dalam merawat kesakitan akut di kalangan kanak-kanak. 
Metodologi: Kanak-kanak berusia diantara 5 hingga 15 tahun yang mengalami kesakitan akut 
pelbagai punca telah dimasukkan ke dalam kajian melalui kaedah persampelan mudah dan 
diberikan rawatan sedutan fentanyl citrate pada dos 4 mcg/kg melalui pemanduan oksigen. 
Kadar kesakitan diperiksa dengan menggunakan Wong and Baker faces pain scale sebelum 
rawatan dan seterusnya setiap 5 minit sehingga satu jam selepas pemberian sedutan fentanyl. 
Tanda-tanda vital direkod dan kesan sampingan rawatan turut dipantau. 
Keputusan: Seramai 42 pesakit yang mengalami kesakitan akut dari pelbagai punca telah 
menyertai kajian ini. Kesemua pesakit menerima rawatan sedutan fentanyl citrate tanpa 
sebarang masalah. 2 pesakit telah dikeluarkan dari kajian berikutan kegagalan rawatan dalam 
mengurangkan kadar kesakitan. Punca-punca kesakitan dikategorikan kepada kepatahan (n= 
14), kecederaan otot dan tisu (n=15) dan sakit perut akut (n= 11). Min markah kesakitan pada 
10 minit pemberian rawatan telah menurun sebanyak 2.65 (95% CI 2.62 hingga 2.73). Markah 
kesakitan terus berkurangan pada minit ke 15 (perbezaan min markah kesakitan 4.20; 95% CI 
4.01 hingga 4.09) diikuti dengan min markah kesakitan yang mendatar dari minit ke 20 
sehingga satu jam setelah rawatan. Pengurangan markah kesakitan pada setiap waktu setelah 
pemberian rawatan sedutan fentanyl adalah sangat signifikan (P < 0.001). Tiada sebarang kesan 
sampingan atau kemerosotan tanda vital diperhatikan berikutan rawatan ini. 
Konklusi: Kaedah rawatan sedutan fentanyl citrate pada dos 4 mcg/kg adalah efektif dalam 
merawat kesakitan akut di kalangan kanak-kanak tanpa menyebabkan sebarang kesan 
sampingan. Kaedah ini adalah disarankan sebagai salah satu cara rawatan dalam perawatan 






Introduction: To assess the effectiveness of nebulized fentanyl citrate in treating children 
presenting with acute severe pain of various aetiologies. 
Methods: Patients aged 5 to 15 years old presented with acute severe pain of any causes were 
enrolled into the study through convenient sampling and received intravenous preparation of 
fentanyl citrate at dose of 4 mcg/kg administered through oxygen driven nebulizer circuit. Pain 
scores were assessed at pre-treatment and subsequently at 5 minutes interval until 60 minutes 
post-treatment using Wong and Baker faces pain scale. Vital signs and potential adverse events 
were also monitored. 
Results: 42 children with acute pain of various causes participated in this study and tolerated 
the nebulized fentanyl citrate well. 2 patients were withdrawn due to insufficient pain control 
post treatment. The pain aetiologies were categorized into fractures (n=14), soft tissue injuries 
(n=15) and abdominal pain (n=11). The mean pain score at 10 minutes on nebulized fentanyl 
administration decreased by 2.65 (95% CI 2.62 to 2.73) from the baseline. Pain score continued 
to decrease at 15 minutes (mean pain score difference 4.20; 95% CI 4.01 to 4.39) followed by 
a sustained plateau pain score at 20 minutes until 60 minutes. The pain score reduction at all-
time intervals measured post-treatment were highly significant (P <0.001). No adverse events 
or vital signs deterioration observed following nebulized fentanyl. 
Conclusion: Nebulized fentanyl citrate at dose of 4 mcg/kg given through oxygen drive 
nebulizer circuit was effective in treating children with acute severe pain without causing 







1.0 INTRODUCTION  
1.1 Introduction 
Acute pain management in children population can be challenging. Children presenting to 
emergency department with acute severe pain require fast and effective pain relieve, yet 
evidence showed on the contrary. One study demonstrated that majority of children with 
painful conditions were less likely to receive adequate analgesia as compared to adult patients 
with similar conditions (Brown et al., 1990). This was supported by subsequent studies 
demonstrating on inadequacy of pain relieve in children with burns and fractures and over one 
third of children with severe fractures did not receive adequate analgesia (Friedland and Kulick, 
1994) (Cimpello et al., 2004). 
Several barriers have been identified in providing adequate pain management in children. 
These include different pain behaviours expressed by children, inadequate assessment due to 
unfamiliarity in scoring pain as well as analgesic dosage among children population, different 
type of paediatric pain scale assessment and reluctance of medical doctors in using more 
invasive techniques such as intramuscular or intravenous routes (Drendel A, 2005).  
Standard approach in providing pain relieve in children with acute pain involve either 
administration of oral or rectal analgesia for mild to moderate painful conditions. More 
significant pain would be treated with parenteral opioid analgesia either by intramuscular or 
intravenous route. Invasive route of analgesia delivery may lead to significant distress and pain 
to the children while application of topical anaesthetic agents prior to IV cannulation may cause 
unacceptable delay in treating acute pain. In addition, peripheral venous cannulation in children 
is associated with a significant higher failure rate compared to adult (Armin Sabri, 2013). 





nebulization or inhalational route may be able to provide rapid and effective pain relieve 
without causing additional pain and distress among children with acute pain. 
1.2 Literature review 
Opioids analgesia remain the mainstay for treatment in acute severe pain regardless whether 
the patient belongs to paediatric or adult group. Briefly, opioids analgesia are broadly divided 
into three main classes with fentanyl being in different class; phenylperidine compared to 
morphine; phenanthrene derivative (MP Sasada, 2011). Opioids are probably used too 
infrequently with inadequate doses in treating children especially due to unfounded fear of 
potential side effects (Verghese and Hannallah, 2010). Most of opioids can be given orally, 
intravenously, rectally or intramuscularly in children population. Adverse effects with opioids 
use include respiratory depression, nausea, vomiting, pruritus, urticarial or hypotension. 
Adverse cardiorespiratory complications with opioid use depends on the child age, weight and 
underlying medical conditions (Verghese and Hannallah, 2010). Infants of less than 3 months 
of age, premature infants, history of apnoea following opioid use, heart, liver or renal diseases 
and head injury have increased risk of cardiorespiratory complications secondary to opioid 
administration. Even though so, the presence of these medical conditions do not preclude the 
use of opioid analgesics. Children with risk factors may safely be treated with opioid by 
titrating the doses and use of lower dosage with continuous monitoring of child’s 
haemodynamic status (ACPeds, 2002; Verghese and Hannallah, 2010). 
Fentanyl is a short acting synthetic opioid approximately one hundred times more potent than 
morphine. Fentanyl has rapid onset of action within one minute when given intravenously due 
to its high lipid solubility and rapid distribution (MP Sasada, 2011). The usual intravenous dose 
in children is 1-2 mcg/kg (Verghese and Hannallah, 2010). Due to difference of opioid classes 





minimal risk of cardiorespiratory depressive effects (MP Sasada, 2011). However, in rare 
occasion fentanyl may potentially cause skeletal and thoracic muscle wall rigidity following 
rapid intravenous ‘push’. This effect is more likely to occur in smaller infants less than six 
months old given with high dose at 5 mcg/kg but may also manifest at lower dosage; 1-2 
mcg/kg especially when given with iv push. Fentanyl induced chest wall rigidity can be 
managed with iv naloxone; opioid antagonist at dose of 0.01 mg/kg, muscle relaxants such as 
suxamethonium or rocuronium and mechanical ventilation (ACPeds, 2002; Verghese and 
Hannallah, 2010). 
Pharmacokinetic studies demonstrated that therapeutic plasma concentration of opioids can be 
achieved through inhalational administration. One of the early pharmacokinetic study on 
inhalational morphine demonstrated that the absolute bioavailability of inhaled opioids were 
approximately 20% of the equivalent intravenous dose though this may vary (Chrubasik et al., 
1988). Consequently, in light of this early pharmacokinetic evidence of inhaled opioid, it is 
highly possible that fentanyl being a potent synthetic opioid with high lipophilic property is 
rapidly absorbed through trans pulmonary mucosa. Further pharmacokinetic study 
demonstrated on the equipotency of intra venous fentanyl to intra venous morphine was at 1 
mcg/kg (Galinski et al., 2005; Gordon, 2007). In view of this, taking into account of 20 % 
absolute bioavailability of inhaled opioid, therefore the suggested nebulized or inhalational 
fentanyl dosage is approximately five times higher than the intravenous route i.e. 5 mcg/kg 
(Farahmand et al., 2014).  
Subsequent pharmacokinetic studies on fentanyl citrate demonstrated variably low absolute 
bioavailability and peak serum concentrations following inhalational route of delivery using 
standard nebulizer circuit (Paut O, 2003; Worsley et al., 1990). There were several factors 
affecting the pharmacokinetic properties of inhalational opioids namely design and 





(Alexander and Rowbotham, 1998). Studies on nebulization apparatus using radiolabelling 
technique demonstrated that only 10% of inhaled dose reached the lungs for trans mucosal 
membrane absorption while the remaining of the drug particles may be deposited in the 
oropharynx and central airways, adhered to the tubing apparatus or loss during exhalation 
(McCallion et al., 1996; Newman et al., 1981) 
The fentanyl serum concentrations following inhalational delivery were found to be much 
lower than the suggested therapeutic threshold; 2 ng/ml in spontaneously breathing subjects. 
The pilot pharmacokinetic study on inhalational fentanyl through standard nebulizer machine 
at 300 mcg produced a low peak serum concentration; 0.4 ng/ml which later plateaued off at 
0.2 ng/ml (Worsely et al., 1990). The lower inhaled fentanyl dosage at 100 mcg only 
demonstrated a plateau serum concentration at 0.1 ng/ml. These findings were supported by 
subsequent pharmacokinetic study which demonstrated on variability of peak serum 
concentration of nebulized fentanyl; 0.63 ng/ml and 1.37 ng/ml with initial concentration of 
250 mcg and 500 mcg respectively; significantly lower compared to control group i.e. 4.36 
ng/ml that received iv fentanyl 100 mcg (Paut et al., 2003). Interestingly, the time taken to 
reach peak serum concentration was within five minute whether fentanyl was given via 
inhalational or IV route. The bioavailability of inhaled fentanyl was found to be less than 30% 
(25% and 29% for concentration of 250 mcg and 500 mcg respectively). Albeit the notably low 
absolute bioavailability and lower peak serum concentration compared to suggested therapeutic 
threshold at 2 ng/ml demonstrated in these studies, fentanyl citrate, being very potent and 
highly lipophilic delivered via inhalational route was sufficient to cause significant pain score 
reduction in studied subjects (Paut O, 2003; Worsley et al., 1990) .  
Alternative methods of opioid delivery are still new in modern medicine world. Studies had 
been done in recent years in assessing evidence to support the efficacy and effectiveness of 





painful conditions among adult and children population (Deaton et al., 2015; Farahmand et al., 
2014; Furyk et al., 2009). However the evidence of inhalational fentanyl in paediatric 
population has not been strong. Till date there were only 2 randomized control trial (RCT) 
involving children population (Furyk et al., 2009; JR Miner, 2007). Furyk et al in 2009 
conducted a RCT comparing the efficacy of nebulized fentanyl to IV morphine in treating 
children with acute severe limb fractures. In the study, a standard nebulizer circuit was used to 
administer the nebulized fentanyl at concentration of 4 mcg/kg lower than the suggested 
nebulized fentanyl dosage at 5 mg/kg. The study demonstrated that nebulized fentanyl was as 
effective as IV morphine in alleviating pain in children with limb fractures. The evidence 
derived from this study was consistent with another RCT conducted in adult population with 
similar inhalational fentanyl dosage i.e. 4 mcg/kg given through standard nebulizer circuit 
(Farahmand et al., 2014). 
The evidence on safety issue of inhaled opioid including fentanyl in treating acute pain is 
limited partly due to the fact that the utilization of pulmonary route for systemic drug delivery 
in pain management is relatively recent approach. The potential side effects of inhalational or 
nebulized fentanyl would be similar to the known side effects associated with its intravenous 
administration. These include drowsiness, vertigo, nausea, vomiting, hypotension, bradycardia 
respiratory depression, cough, bronchospasm, muscular rigidity and allergic reactions. The 
potential direct respiratory side effects of nebulized opioid especially cough or bronchospasm 
would not be of a major concern with regard to fentanyl citrate as it is associated with minimal 
allergic risk due to insignificant fentanyl induced histamine release as opposed to morphine 
(MP Sasada, 2011). While inhalational opioid is still a new approach in pain management, 
nebulized opioids including fentanyl citrate have already been widely used in treating patient 
with respiratory symptoms in terminal cancer and other respiratory disease. Nebulized fentanyl 





saturation in terminally ill cancer patient without causing any direct adverse effects to the 
airway including bronchospasm (Chandler, 1999; Coyne et al., 2002; Graff et al., 2004). With 
regard to inhalational fentanyl in acute pain management, there was no significant adverse 
events demonstrated since previous pharmacokinetic studies (Paut O, 2003; Worsley et al., 
1990). The RCTs in children did not encounter any adverse events related to administration of 
fentanyl citrate by inhalational method (Furyk et al., 2009; Miner, 2010). There was no 
significant change in term of Glasgow Coma Score, Ramsay Sedation Score, blood pressure, 
respiratory rate or oxygen saturation. The RCT involving adult population also demonstrated 
on efficacy of nebulized fentanyl citrate without any significant adverse events. (Bartfield et 
al., 2003; Deaton et al., 2015; Farahmand et al., 2014). No instances of antidote naloxone 
administration or resuscitative measures such as intubation or ventilation were necessary in all 
RCTs involving adult and paediatric populations. Even though more work is required to 
address on the safety concern of inhalational fentanyl, the available evidence so far 
demonstrated that nebulization fentanyl is both effective and safe. 
There are numerous measures and scales for assessing children’s pain which can be classified 
as physiological, behavioural or self-report, depending on the nature of the response that is 
measured. The physiological parameters of pain may include tachycardia, crying, sweating, 
blood pressure elevation, flushing and muscle tension. However none of these physiological 
changes are neither sensitive nor correlate directly with a child experiencing pain. These 
parameters can be confounded especially by fear, anxiety or fever (Liebelt, 2000). The 
observation of child’s behaviour during acute pain is another method of pain measurement. 
Presence of brow bulge, eye squeeze, nasolabial furrow, open lips, horizontal stretch mouth 
and chin quiver may provide  an assessment of infant pain expression (Liebelt, 2000). The 
Children’s Hospital of Eastern Ontario Pain Scale (CHEOPS) is reliable in children under age 





expression, verbal expression, torso position, touch behaviour and leg position – on a 13 point 
scale ranging from 4 ( no pain) to 13 (worst pain) (McGrath et al., 1998). On the other hand, 
the faces pain scales are more popular pain measures compared to other pain assessment tools 
as they are simple to use and most children can readily identify with facial expression of actual 
children or cartoon drawing. The faces pain scales self-report measures on pain intensity in 
acute, procedural and recurrent pain that can be used reliably for developmentally normal 
children over four years of age (Chambers et al., 1998). One of the most widely used and best 
validated faces pain scales is Wong and Baker Faces Pain Scale (WBFPS) (Figure 1). The 
WBFPS is a well validated, self-reported pain scale commonly used to assess pain in children 
above four years of age (Bosenberg et al., 2003; Tomlinson et al., 2010) The pain scale consists 
of six cartoon-like faces, with different pain expression. Each face scale reflects the number of 
pain score (0-10). ‘NO HURT’ reflects pain score of 0/10 whereas ‘HURT WORST’ signifies 
very severe pain; pain score 10/10. The strength of this scale is its acceptability, given the 
consistency finding that it is preferred by children, parents and practitioners when compared to 











1.3    Justification of study 
The ideal pain management in children population should be efficacious, providing rapid pain 
relieve, easy to administer and most importantly does not cause additional pain or discomfort. 
Undoubtedly, intramuscular and intravenous route of analgesia delivery would cause more pain 
and distress to children who is already in pain. Although intravenous analgesia provides 
advantageous of quick relief and easily titrated, peripheral cannulation can be challenging in 
any circumstances while intramuscular administration has delayed onset of action, difficult 
titration and is more painful. Therefore availability of alternative methods of providing fast and 
rapid analgesia such as inhalational or nebulize route may improve patients care by reducing 
analgesia time without causing further discomfort and pain. As fentanyl pharmacokinetic 
properties being highly potent and lipid soluble make it well suited opioid analgesia to be 
delivered via trans pulmonary delivery. 
The evidence on effectiveness of trans pulmonary delivery of fentanyl is limited as inhalational 
method of opioid delivery is still naive in medical practice. Of particular, there was only one 
RCT in children in looking into the efficacy of nebulized fentanyl delivered using standard 
nebulizer circuit in treating children with suspected limb fracture (Furyk et al., 2009). Although 
the RCT demonstrated favourable outcome but with number of limitations namely small 
sample size and short duration of study period, new evidence derive from this study will 
strengthen the available evidence hence forth may serve as preliminary data for further research 








1.4  Objectives of study 
General Objective 
To assess the effectiveness of nebulized fentanyl citrate in treating children with acute severe 
pain. 
 
Specific Objectives  
I. To determine the effectiveness of nebulized fentanyl citrate in reducing pain score in 
children with acute severe pain of various aetiologies. 
II. The primary end point is to analyze whether administration of nebulized fentanyl citrate 
using a standard nebulizer circuit will result in significant decrease on pain score among 
children with acute pain. 


















CHAPTER 2: STUDY PROTOCOL 
2.1 Study protocol submitted for ethical approval 
Study design  
This is a single arm prospective interventional clinical study. The study does not include 
randomization or placebo control. The primary end point is to evaluate the effectiveness of 
nebulized fentanyl in causing clinically significant pain score reduction in children presented 
to our emergency department with acute severe pain of various aetiologies. The main purpose 
of this study is to advocate fast and effective analgesia delivery in children without causing 
other unnecessary pain and discomfort. As peripheral venous cannulation in children is 
associated with high failure rate, this may potentially cause increase in dropout rate which may 
negatively affect the study protocol. Furthermore, administration of nebulized placebo is not 
ethically or humanly acceptable in treating acute severe pain. In addition, this is also to avoid 
protocol violation  which had occurred in one previous RCT in which the parents requested for 
their children to be in nebulized fentanyl group as to avoid intravenous cannulation if possible 
(Miner et al., 2007). 
 
Study duration 
Study duration is planned from January 2017 until Mac 2017. 
 
Study location 










Children presenting to Emergency Department Hospital Universiti Sains Malaysia with acute 
pain of various cause. 
 
Study population 
Children aged five to fifteen years old presenting to Emergency Department Hospital Universiti 




Children aged five to fifteen years old presenting to Emergency Department Hospital Universiti 
Sains Malaysia with acute pain of various cause in the period from January 2017 till Mac 2017 
and fulfill inclusion and exclusion criteria. 
 
INCLUSION AND EXCLUSION CRITERIA 
Inclusion Criteria 
i. Children aged five to fifteen years old with acute pain of various aetiologies 
presented to Emergency Department Hospital Sains Malaysia. 
ii. Pain score > 6 /10 assessed by Wong & Baker Faces Pain Scale (WBFPS) 
iii. American Society of Anaesthesiologist (ASA) classification I or II. 
iv. Consented parents or legal guardians. 
 
Exclusion criteria 






ii. Underlying bronchial asthma on preventer or having acute exacerbation on 
presentation. 
iii. Concurrent upper respiratory tract infection. 
iv. Concurrent lower respiratory tract infection. 
v. Concurrent head injury including cerebral concussion. 
vi. ASA classification > II. 
vii. received iv narcotics (opioids) or any other oral, parenteral and suppository analgesia 
four hours prior to presentation  
viii. Known allergy to opiod analgesia. 
ix. Pain score < 6/10 assessed by Wong & Baker Faces Pain Scale (WBFPS) 
 
Sampling Method 
Convenience sampling will be used for sampling method. All children aged five to fifteen years 
old with acute severe pain of various aetiologies (pain score > 6/10 on WBFPS), fulfill 
inclusion and exclusion criteria and consented by parents or legal guardians will be included 
in the study. 
 
Sample Size Calculation 
Sample size calculation is determined using software PS: Power & Sample Size Calculation 
Version 3.1.2. 2014 developed by William D. Dupont and Walter D. Plummer Jr. 
The details on sample size calculations are as follow: 
 Standard Deviation SD: 2.2 (Furyk et al., 2009) 






 Power of study: 80% 
 Type 1 error (α): 0.05  Zα: 1.96 (normal deviation reflecting Type 1 error /  95% CI) 
 Consider 10% drop out rate 







 Research protocols and data collection 
Eligibility of patients to be included in the study will be determined by age group, inclusion 
and exclusion criteria as was listed above. Suitable candidate will be sampled into the study 
only after written consent has been obtained from the parents and legal guardians. Assent will 
also be obtained from children above twelve years old. Details of the study protocols which 
include the aim and the objectives, flow and study procedures as well as complication 
monitoring will be addressed in written consent. 
Study procedures will be carried out in yellow zone with availability of emergency trolley. 
The procedures will neither interrupt nor changed patients’ definitive management. 
Intravenous cannulation and blood taking procedure would still be done after patient have 
achieved satisfactory control over severe pain. Topical anaesthetic agent will be applied 
shortly after enrolment to facilitate peripheral venous cannulation. 
Demographic information and initial vital signs with pain score assessment will be recorded 
prior to treatment with nebulized fentanyl citrate. The pre- treatment parameters are as 
following: 
Demographic parameters: 
1. Age (years) 
2. Gender (Male, Female) 
3. Weight (kg) 
4. Underlying medical conditions  
a. Heart disease 
b. Liver disease 
c. Renal disease 





e. Bronchial asthma 
f. Known allergy to opioid analgesia 
5. ASA classification 
6. Diagnosis on presentation 
Vital signs parameters: 
1. Glasgow Coma Scale (GCS) 
2. Ramsay Sedation score (RSS) 
3. Blood pressure (BP) 
4. Heart rate (HR) 
5. Respiratory rate (RR) 
6. Oxygen saturation (SPO 2) 
7. Pain score  
 Pain score assessment will be done using the Wong and Baker Faces Pain Scale (WBFPS) 
(Wong DL, 1997) (Figure 1). The pain scale consists of six cartoon-like faces, with different 
pain expression. Each face scale reflects the number of pain score (0-10). ‘NO HURT’ 
reflects pain score of 0/10 whereas ‘HURT WORST’ signifies very severe pain; pain score 
10/10. Patients will be shown the pain scale and they chose the most appropriate cartoon-like 
face that reflect their pain. In this study, the pain score assessment will be done by different 
doctors and they will be blinded from each previous pain score assessment. Children that is 
not able to score the pain will be excluded from the study.  
 





Nebulized fentanyl is prepared by mixing the intravenous preparation of fentanyl citrate, 
calculated at 4 mcg/kg with 0.9% normal saline to a five cc solution. Of note, previous works 
had also used intravenous preparation of fentanyl citrate in their studies (Farahmand et al., 
2014; Furyk et al., 2009; Miner et al., 2007). The maximum dosage of fentanyl citrate is 200 
mcg regardless whether the calculated dosage exceeded body weight. The medication will be 
administered to patients as oxygen driven nebulization at 5 L/ min using a standard nebulizer 
circuit available in our emergency department. The nebulization time is approximately ten 
minutes of administration. Continuous vital signs monitoring will be done throughout study 
period. Subsequently, vital signs recording including GCS, RSS, BP, HR, RR, SPO2 and pain 
score will be done serially at five minutes interval until sixty minutes post nebulized fentanyl 
administration. 
Treatment failure is determined by unsatisfactory pain control ten minutes on administration 
of nebulized fentanyl or increasing pain during observation period. Treatment would be 
reverted to standard care which include immediate placement of peripheral venous 
cannulation and administration of iv morphine at 0.5 mg every five minute until satisfactory 
pain control achieved or to a total of 0.1 mg/kg. This is determined at the discretion of 
attending physician and will be considered as treatment failure. Patients would also be 
withdrawn from the study if they develop any adverse effects related to fentanyl citrate 
administration. Any adverse events would be recorded and addressed immediately with 









Adverse effects monitoring and interventions 
Continuous vital signs monitoring will be done throughout the procedures. Potential side 
effects of the treatment will be monitored, recorded and treated accordingly. Iv Naloxone, an 
opioid antagonist will be made available by bed side along with emergency trolley equipped 
with advanced airway intervention devices. The potential side effects are as following: 
1. Hypotension 
2. Bradycardia  
3. Apnoea  
4. Bronchospasm 
5. Oxygen desaturation 
6. Nausea & vomiting 
7. Drop in GCS 
8. Anaphylactic reaction 
9. Muscular rigidity 
The potential risk of direct respiratory side effects of nebulized opioid for instance cough or 
bronchospasm is minimal as previous works have demonstrated on efficacy of nebulized 
fentanyl citrate and morphine from intravenous preparation as treatment of dyspnoea in 
terminal cancer and respiratory disease without causing any undesired aforementioned side 
effects (Chandler, 1999; Coyne et al., 2002; Graff et al., 2004). Moreover, unlike morphine 
fentanyl cause insignificant histamine release thus has minimal risk of anaphylactic reactions 
such as airway obstruction, cough, bronchospasm or hypotension (MP Sasada, 2011; 
Tintinalli JE, 2004). 
Of note, none of RCT on nebulized Fentanyl Citrate involving adult and paediatric population 





et al., 2015; Farahmand et al., 2014; Furyk et al., 2009; JR Miner, 2007) No instances of 
antidote naloxone administration or resuscitative measures such as intubation or ventilation 
were necessary in all RCTs involving adult and paediatric populations. Even though more work 
is required to address on the safety concern of inhalational fentanyl, the available evidence so 
far demonstrated that nebulization fentanyl is both effective and safe. (Please refer to literature 
review page 6-7). 
 The specific management and interventions of above mentioned potential side effects are 
addressed in detailed in Appendix A 
Data entry and data analysis 
Statistical analysis will be done using Statistical Packages for Social Science (SPSS) version 
22.0. Descriptive analysis will be expressed in frequencies and percentage for categorical 
variables. Means and standard deviation will be expressed in numerical variables. Difference 
between pain scores at pre-treatment and 10, 15, 20, 25, 30, 35, 40, 45, 50, 55 and 60 minutes 
post treatment will be assessed using paired t-test and repeated measure analysis of variance 
(ANOVA). A p value < 0.05 is considered as statistically significant for all statistical analysis 
in this study. A 95% confidence interval; CI will be calculated for the primary outcome of 
decrease in pain score in between time intervals post treatment. Decrease of one unit of faces 
pain scale is selected as the minimum clinically significant difference (MCSD) of pain score 
reduction. This is in line with previous works demonstrating that  the minimum clinically 
significant reduction of pain score in children is either 10 mm on the 100 mm visual analogue 








Data Privacy & Confidentiality 
All information, copy of informed consent and data collected during the study procedure will 
be properly stored and locked in a locker in a designated area within Emergency Department 
of Hospital Universiti Sains Malaysia. All aspects concerning privacy and confidentiality will 
be maintained at all time and the data and information would only be accessible to primary 




Inform written consent will be obtained before inclusion into this study. 
Ethical approval will be obtained from the Research and Ethics Committee of the School of 






































Assessment for eligibility 
 Children age: 5 -15 years old  
 Acute severe pain of various aetiologies 
(Wong & Baker Faces Pain Scale 6/10) 
Pre- Treatment  
 (n = 42) 
 Vital signs + Pain score  
Post – Treatment 
 Vital signs & Pain score at 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 minutes post 
treatment 
 Side effects monitoring  
Treatment 
Nebulized Fentanyl at 4 mcg/kg via 
oxygen drive using standard 
nebulizer circuit 
Data Entry & Analysis  
Exclusion 
- Not meeting inclusion criteria 
- Pain score < 6 /10 
- Non consented parents/ legal 
guardians 
Withdrawal from treatment 
- Increasing pain or insufficient 
pain score reduction 10 






STUDY ON THE EFFECTIVENESS OF NEBULIZED FENTANYL AS MODALITY OF 
ANALGESIA IN CHILDREN WITH ACUTE PAIN RESEARCH PROTOCOL 
PRIMARY INVESTIGATOR: DR RADEN NEZARUL BIN RADEN YAHAYA 
SUPERVISOR: DR ABU YAZID BIN MD NOH 
INCLUSION AND EXCLUSION CRITERIA 
Inclusion Criteria 
v. Children aged 5 to 15 years old with acute pain of various aetiologies presented to 
Emergency Department Hospital Sains Malaysia. 
vi. Pain score > 6 /10 assessed by Wong & Baker Faces Pain Scale (WBFPS) 
vii. American Society of Anaesthesiologist (ASA) classification I or II. 
viii. Consented parents or legal guardians. 
 
Exclusion criteria 
x. Underlying medical conditions which include heart, liver, renal diseases and malignancy. 
xi. Underlying bronchial asthma on preventer or having acute exacerbation on presentation. 
**Patient with bronchial asthma is eligible if not on preventer inhaler and having acute 
exacerbation on enrollment. 
xii. Concurrent upper respiratory tract infection. 
xiii. Concurrent lower respiratory tract infection. 
xiv. Concurrent head injury including cerebral concussion. 
xv. ASA classification > II. 
xvi. Received iv narcotics (opioids) or any other oral, parenteral and suppository analgesia four 
hours prior to presentation  
xvii. Known allergy to opiod analgesia. 






STUDY ON EFFECTIVENESS OF NEBULIZED FENTANYL AS MODALITY OF 
ANALGESIA IN CHILDREN WITH ACUTE PAIN 
DATA COLLECTION FORM/PROFOMA 
Demographic Data 
Age:   Date/RN:   Gender: M/F   Weight: 
Underlying medical conditions: EXCLUDE IF PATIENT HAS ANY OF THESE 
CRITERIA 
i. Heart disease       : Y / N 
ii. Liver disease        : Y / N 
iii. Renal disease        : Y / N 
iv. Malignancy       : Y / N 
v. Bronchial Asthma (on preventer or current exacerbation)  : Y / N 
vi. Concurrent upper or lower respiratory tract infection : Y / N 
vii. Head injury including cerebral concussion   : Y / N 
viii. Known history of allergy to opioids analgesia   : Y / N 











AMERICAN SOCIETY OF ANAESTHESIOLOGY RISK CLASSIFICATION (ASA) 
Class Condition 
I Normal healthy patient with no systemic illness 
II Mild to moderate systemic disease 
III Severe systemic disease with functional limitation that is otherwise 
incapacitating 
IV Severe systemic disease that is incapacitating and life threatening 
V Moribund patient not expected to survive 24 hours without surgical 
interventions 
 
INSTRUCTION OF MEDICATION PREPARATION AND METHODS OF 
ADMINISTRATION 
1. Calculate 4 mcg/kg (max 200mcg) of Fentanyl Citrate & mix with 0.9% Normal 
Saline solution to make up to 5cc solutions. 
a. DRUG DOSE: _________  
2. Administer the medication to patient via oxygen drive nebulization at 5 L / min using 
standard nebulizer circuit available in emergency department. 
3. Make sure SPO2 and HR is monitored throughout the procedures. 
4. If patient still having severe pain 10 minutes after nebulization, rescue medication 
should be given. 
a. Give IV morphine at dose of 0.5 mg per minute to total dose of 0.1 mg/kg 
i. Dose of IV morphine :  
5. Criteria of withdrawal from the study: 





b. Parents/legal guardian request 
c. Treatment failure -require rescue medications 
d. Adverse events requiring interventions 
 
RAMSAY LEVEL OF SEDATION 
Level of Sedation Score 
Awake Levels 
Patient either anxious or agitated or both 1 
Patient is tranquil, cooperative & orientated 2 
Patient respond only to command 3 
Asleep level 
Brisk response to light glabellar tap or loud auditory stimulus 4 
Sluggish response to light glabellar tap or loud auditory stimulus 5 
No response to painful stimuli 6 
** Reference: M. A. E Ramsay 
WONG & BAKER FACES PAIN SCALE 
 
 
 
